VRCA vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about Verrica Pharmaceuticals Inc. (VRCA) and Novo Nordisk A/S (NVO).

Performance

VRCA vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verrica Pharmaceuticals Inc. (VRCA) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

VRCA vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
VRCA Verrica Pharmaceuticals Inc.	-33.94%	18.71%	-90.44%	166.18%	-69.98%	-20.42%	-27.56%	94.97%	-53.43%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	2.74%

Fundamentals

Market Cap VRCA : $58.48M NVO : $162.26B
EPS VRCA : -$1.81 NVO : $22.15
PS Ratio VRCA : 1.52 NVO : 0.55
PB Ratio VRCA : 2.36 NVO : 0.84
Total Revenue (TTM) VRCA : $35.58M NVO : $297.20B
Gross Profit (TTM) VRCA : $33.39M NVO : $240.66B
EBITDA (TTM) VRCA : -$12.19M NVO : $153.18B

Returns By Period

In the year-to-date period, VRCA achieves a -33.94% return, which is significantly lower than NVO's -25.80% return.

VRCA

• 1D: 3.78%
• 1M: 2.23%
• YTD: -33.94%
• 6M: 23.65%
• 1Y: 30.53%
• 3Y*: -56.12%
• 5Y*: -48.62%
• 10Y*: —

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VRCA vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRCA

VRCA Risk / Return Rank: 54
VRCA Sharpe Ratio Rank: 50
VRCA Sortino Ratio Rank: 63
VRCA Omega Ratio Rank: 58
VRCA Calmar Ratio Rank: 49
VRCA Martin Ratio Rank: 48

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRCA vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verrica Pharmaceuticals Inc. (VRCA) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VRCA	NVO	Difference
Sharpe ratio Return per unit of total volatility	0.28	-0.81	+1.09
Sortino ratio Return per unit of downside risk	1.33	-0.99	+2.32
Omega ratio Gain probability vs. loss probability	1.15	0.86	+0.29
Calmar ratio Return relative to maximum drawdown	0.39	-0.82	+1.21
Martin ratio Return relative to average drawdown	0.72	-1.41	+2.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VRCA vs. NVO - Sharpe Ratio Comparison

The current VRCA Sharpe Ratio is 0.28, which is higher than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of VRCA and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VRCA	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.28	-0.81	+1.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.49	0.10	-0.59
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.38	0.46	-0.84

Correlation

The correlation between VRCA and NVO is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VRCA vs. NVO - Dividend Comparison

VRCA has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.94%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
VRCA Verrica Pharmaceuticals Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

VRCA vs. NVO - Drawdown Comparison

The maximum VRCA drawdown since its inception was -98.39%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for VRCA and NVO.

Drawdown Indicators

	VRCA	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-98.39%	-74.70%	-23.69%
Max Drawdown (1Y) Largest decline over 1 year	-62.41%	-55.03%	-7.38%
Max Drawdown (5Y) Largest decline over 5 years	-97.86%	-74.70%	-23.16%
Max Drawdown (10Y) Largest decline over 10 years	—	-74.70%	—
Current Drawdown Current decline from peak	-97.30%	-73.49%	-23.81%
Average Drawdown Average peak-to-trough decline	-63.32%	-17.56%	-45.76%
Ulcer Index Depth and duration of drawdowns from previous peaks	33.46%	31.83%	+1.63%

Volatility

VRCA vs. NVO - Volatility Comparison

Verrica Pharmaceuticals Inc. (VRCA) has a higher volatility of 27.05% compared to Novo Nordisk A/S (NVO) at 9.39%. This indicates that VRCA's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VRCA	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	27.05%	9.39%	+17.66%
Volatility (6M) Calculated over the trailing 6-month period	74.86%	38.79%	+36.07%
Volatility (1Y) Calculated over the trailing 1-year period	109.40%	54.16%	+55.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	99.45%	37.82%	+61.63%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	95.76%	32.28%	+63.48%

Financials